YCG
GILD icon

Yeomans Consulting Group’s Gilead Sciences GILD Stock Holding History

Yeomans Consulting Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,633
Closed -$295K – 104
2025
Q1 		$295K Buy
+2,633
New +$272K 0.11% 53

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Yeomans Consulting Group's GILD Position: Q2 2025 in Review

Yeomans Consulting Group sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 2,633 shares — an estimated $295K sold.

Yeomans Consulting Group first reported a position in GILD in Q1 2025 and held it in 1 quarter. The position peaked at $295K in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Yeomans Consulting Group reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Yeomans Consulting Group sold 2,633 Gilead Sciences shares in Q2 2025, an estimated $295K.
  • Yeomans Consulting Group first reported a position in Gilead Sciences in Q1 2025 and held it in 1 quarter.
  • Yeomans Consulting Group's Gilead Sciences position peaked at $295K in Q1 2025.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Yeomans Consulting Group's 13F filing for Q2 2025, filed 21 Jul 2025.